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Abstract
Deep brain stimulation (DBS) is currently tested as an experimental therapy for patients with treatment-
resistant depression (TRD). Here we report on the short- and long-term (1 yr) clinical outcomes and
tolerance of DBS in eight TRD patients. Electrodes were implanted bilaterally in the subgenual cingulate
gyrus (SCG; Broadman areas 24–25), and stimulated at 135 Hz (90-ms pulsewidth). Voltage and active
electrode contacts were adjusted to maximize short-term responses. Clinical assessments included the
17-item Hamilton Depression Rating Scale (HAMD17 ; primary measure), the Montgomery–A˚sberg
Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) Scale. In the ﬁrst week after
surgery, response and remission (HAMD f7) rates were, respectively 87.5% and 50%. These early re-
sponses were followed by an overall worsening, with a response and remission rates of 37.5% (3/8) at
1 month. From then onwards, patients showed a progressive improvement, with response and
remission rates of 87.5% and 37.5%, respectively, at 6 months. The corresponding ﬁgures at 1 yr were
62.5% and 50%, respectively. Clinical eﬀects were seen in all HAMD subscales without a signiﬁcant
incidence of side-eﬀects. Surgical procedure and post-operative period were well-tolerated for all patients.
This is the second independent study on the use of DBS of the SCG to treat chronic depression resistant to
current therapeutic strategies. DBS fully remitted 50% of the patients at 1 yr, supporting its validity as a
new therapeutic strategy for TRD.
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Introduction
Major depressive disorder (MDD) has a lifetime
prevalence of y15–20% (Kessler et al. 2005), and it is
one of the leading causes of disability worldwide
(Giacobbe et al. 2009) as is often accompanied by
high rates of resistance to treatment. The STAR*D trial
reported that up to 33% of patients do not reach re-
mission criteria after four sequenced treatments (Rush
et al. 2006), leaving clinicians with few therapeutic
options to alleviate the sadness, hopelessness, lack of
pleasure and suicidal thoughts in chronic depressive
patients.
Electroconvulsive therapy (ECT) is a long-
established alternative strategy for treatment-resistant
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depression (TRD). However, a considerable pro-
portion of patients do not respond, experience fre-
quent relapses, or do not tolerate its adverse eﬀects,
mainly memory disturbances (Kellner et al. 2006).
Other non-invasive methods, such as transcranial
magnetic stimulation (TMS) raised interest for the
treatment of drug-resistant depression. However, this
technique shows highly heterogeneous results (Avery
et al. 2006; Burt et al. 2002; Fregni et al. 2005).
On the other hand, deep brain stimulation (DBS)
is currently tested as an experimental therapy for
patients with TRD. DBS involves the high-frequency
electrical stimulation of stereotaxically implanted
electrodes in certain brain regions, such as the sub-
thalamic nucleus for drug-resistant Parkinson’s dis-
ease (Limousin et al. 1998). DBS has shown promising
results in TRD so far, and may become a new thera-
peutic opportunity for chronic, treatment-refractory
patients, with few adverse eﬀects. DBS may modulate
nerve transmission in cortico-striatal-thalamo-cortical
loops in a reversible and adjustable manner (Mayberg,
2009). Various target areas have been examined for
DBS to modulate cortico-limbic circuits, including
the anterior limb of the internal capsule, the ventral
capsule/ventral striatum (VC/VS), the nucleus ac-
cumbens (NAc), and Brodmann area (BA) 25 [sub-
genual cingulate gyrus (SCG)]. Mayberg and
colleagues (Kennedy et al. 2011; Lozano et al. 2008;
Mayberg et al. 2005) reported that 60% of TRD patients
subjected to DBS of the subgenual cingulate (Cg25)
experienced a response [o50% reduction of Hamilton
Depression Rating Scale (HAMD) score] and 35%
fulﬁlled the criterion for remission (HAMD scoref7)
after 6 months of stimulation. The response rates were
reasonably maintained after 1, 3 and 6 yr. Moreover,
50% of the patients subjected to DBS of NAc re-
sponded in a 1-yr observation period (Bewernick et al.
2010; Schlaepfer et al. 2008). Electrode implantation in
the VC/VS also provided response rates of 40% and
y50% at 6 and 24 months, respectively (Malone et al.
2009).
Cg25 may play a key role in the control of cortico-
limbic circuits given its connectivity with brain
structures involved in aﬀective disorders, namely
the anterior cingulate cortex, the amygdala, the
caudate nucleus and the thalamus, which feed back
onto the prefrontal cortex and cingulate cortex, closing
a limbic loop. The possibility of modulating a pre-
sumably dysfunctional activity of this circuit from
the SCG should provide a good opportunity to bear
upon the broad spectrum of depressive symptoms
(Phillips et al. 2003; Seminowicz et al. 2004), as sug-
gested by the robust antidepressant eﬀects observed in
the ﬁrst sample of TRD patients receiving SCG
DBS (Kennedy et al. 2011; Lozano et al. 2008; Mayberg
et al. 2005).
The current study aims at replicating and extending
the latter ﬁndings. Thus, we describe here the short-
and long-term clinical outcomes and tolerance of
SCG stimulation in a new independent sample of eight
patients with TRD.
Methods and materials
We report on the preliminary ﬁndings of the pre-
randomization period of a randomized controlled
and cross-over clinical trial. In this initial phase of
the study electrodes were implanted in all patients
and chronic stimulation started within the ﬁrst 48 h
after surgery. The length of this study phase varied
depending on the time required by each patient
to achieve clinical stability, i.e. <10% variation in
HAMD scores in o3 consecutive visits after reaching
the criterion of response, thus more than the 9-month
period we initially anticipated. Here we report the
ﬁndings of 1 yr follow-up.
Patient selection
Eight patients with TRD were included in the study.
They were recruited from the Hospital de la Santa
Creu i Sant Pau from January 2008 to December 2009.
A committee composed of the patients’ psychiatrist,
an independent psychiatric consultant, a neurologist
and a neurosurgeon decided which patients could be
enrolled in the study, by pre-selecting subjects among
the most treatment-resistant patients. All selected
patients agreed to be included in the study. All pa-
tients were properly informed of the aims and risks of
the study and signed an informed consent form after
meeting with both the psychiatrist and neurosurgeon.
The study was approved by the hospital ethical com-
mittee and the Agencia Espan˜ola de Medicamentos
y Productos Sanitarios (Spanish regulatory drug
agency).
Inclusion criteria
Individuals aged 18–70 yr diagnosed as having a
major depressive episode according to DSM-IV-TR
criteria, resistant to pharmacological treatment, at
least in stage IV of the Thase–Rush scale (Thase &
Rush, 1997) and with lack of eﬃcacy of ECT or partial
response to maintenance ECT. Admission score on the
17-item HAMD (HAMD17) had to be o18. Patients
should have not modiﬁed their antidepressant treat-
ment in the previous month prior to study inclusion.
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Exclusion criteria
Acute, serious or unstable comorbid neurological or
medical illness, current or past non-aﬀective psychotic
disorder, severe personality disorder that could im-
pact tolerance or compliance during the study, current
substance abuse or dependence (except nicotine), sur-
gical contraindications to undergoing DBS and preg-
nancy.
Clinical assessments
Demographics were collected from all patients.
Blood samples were obtained in order to determine
presurgical conditions and antidepressant plasma le-
vels. A psychiatric screening was performed by means
of Structured Clinical Interview for DSM-IV Axis I
and II (SCID; First et al. 1997, 2002). Assessments in-
cluded HAMD17 (primary measure) (Hamilton, 1967),
the Montgomery–A˚sberg Depression Rating Scale
(MADRS; Montgomery & A˚sberg, 1979), and the
Clinical Global Impression Scale (CGI; Ikadouri et al.
2007) which were collected to evaluate changes on
clinical outcomes. Response was deﬁned as a decrease
of o50% of baseline HAMD17 score. Remission was
deﬁned as a score of f7 in HAMD17. Patients were
visited at least twice a month throughout this study
period (12 months) to assess eﬃcacy.
Cognitive functioning was assessed at baseline
and after clinical stabilization by means of a compre-
hensive neuropsychological battery (general intellec-
tual ability, learning, memory, executive function,
language and processing speed).
Surgical procedure
Surgical electrode implantation was performed in the
white matter adjacent to the Cg25 region and the DBS
pulse-generating device was implanted abdominally.
Prior to surgery, a Leksell G stereotactic frame (Elekta
Instruments, USA) was ﬁtted to the patient’s head.
Using the neuronavigator (BrainLab model 1.19) the
CT scan with the stereotactic frame was fused to the
MRI image to calculate the surgical target. The target
SCG white matter was delimited as follows: in a
midline T2 sagittal image the cingulate gyrus below
the genu of the corpus callosum was identiﬁed; next, a
line was traced from this point of the corpus callosum
to the anterior commissure and the mid-point was
identiﬁed; an image was then taken of the T2 coronal
section corresponding to the plane of the mid-point
and the deﬁnitive coordinates were calculated for the
transition area between the white and grey matter for
BA 25 (based on Mayberg et al. 2005). In the operating
room, with the patient under local anaesthesia, a burr
hole was drilled 2 cm from the midline in front of the
coronal suture.
Intra-operative neurophysiological extracellular re-
cordings started 10 mm above the target. Cell activity
was ampliﬁed and analysed in an oscilloscope and
an audio monitor (Leadpoint, Medtronic, USA).
Extracellular recordings were performed to identify
the transition between grey and white matter in BA 25
where the electrodes were implanted. DBS electrodes
(Medtronic model 3387) were implanted bilaterally.
Each of the four electrode contacts was tested intra-
operatively at maximal voltage (9.0 V) to study ad-
verse eﬀects and subjective feelings. During the same
surgical procedure, a programmable internal pulse
generator (Kinetra, Medtronic) was implanted sub-
cutaneously under general anaesthesia in the tissue of
the abdominal wall.
Patients were discharged 4–8 d after surgery. A
high-resolution 3D T1-weighted MRI was obtained
using a dedicated protocol on 1.5 T Philips equipment
within the ﬁrst 2 months after surgery in order to
check the electrode localization.
Stimulation settings
In the 1–5 d after surgery, stimulation parameters
(voltage, frequency, etc.) were adjusted prior to start-
ing chronic stimulation. Acute changes observed dur-
ing single-blind sequential stimulation (e.g. patients
were unaware whether DBS was being performed or
not) were recorded. Based on the parameters used for
Parkinson’s disease and on previous work by Lozano
et al. (2008), the ﬁrst three patients were stimulated as
follows: continuous monopolar stimulation at 3.6 V
(135 Hz, 90-ms pulsewidth) using the most ventral
electrode contacts. The sequence of changes to max-
imize the therapeutic eﬀect was (1) to increase voltage,
(2) to increase pulsewidth, and (3) to change active
contacts. Electrode contacts and current stimulation
parameters in each patient are shown in Fig. 1. In the
ﬁrst three patients, bipolar stimulation was required
for better clinical eﬀects. Subsequently, bipolar stimu-
lation was used in the rest of patients using similar
stimulation parameters. Mean voltage was 4.2 V
(range 3.5–5 V).
Statistical analysis
Sample descriptive analyses were performed with
parametric and non-parametric tests. To evaluate
clinical response, data from all rating scales were
analysed with ANOVA for repeated measures with
time as within-subjects factor (baseline, 1, 2, 4, 6, 9, 12
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months) followed by post-hoc t tests vs. baseline.
Additional analyses were performed using t tests or
ANOVA, as appropriate. Signiﬁcance level was set at
5% (two-tailed). Last observation carried forward
analysis was applied for missing data.
Results
Patients ’ characteristics
Subjects ’ clinical and demographic characteristics are
shown in Table 1. The HAMD17 mean score was 21.3
(S.D.=2.4) at entry. The mean age at onset of disease
was 24.9 (S.D.=5.3) yr and the mean age at electrode
implant was 47.4 (S.D.=11.3) yr. Duration of the
current episode was 6.3 (S.D.=1.8) yr. The length of
follow-up period was 1 yr.
All patients had failed in multiple trials of phar-
macotherapy and six of them also failed in adequate
individual psychotherapy. Included patients had
shown good treatment responses in the early stages of
the disorder, and they became treatment-resistant over
the course of the illness (see Table 2a for a summary of
treatment history of each patient). In this regard, all
patients had received ECT, four of which showed
partial response to maintenance ECT before DBS.
At the time of surgery, all patients were being
treated with one or two antidepressant drugs from
diﬀerent families, combined with one or several of the
following drugs: a mood stabilizer (lithium, valproate,
lamotrigine), an atypical antipsychotic or an anxiolytic
(benzodiazepine or pregabalin). Maintenance ECT
(received by four patients, with partial response)
was stopped 2 wk before inclusion in the study.
Antidepressant drugs were not changed during the
follow-up period; benzodiazepines and antipsychotic
drugs were reduced in parallel with clinical improve-
ment. Patient 4 suﬀered tricyclic antidepressant in-
toxication due to drug interaction within the ﬁrst
month after intervention, so the antidepressant drug
had to be changed to a SSRI ; this patient did not
respond to DBS at the end of follow-up. A detailed
description of baseline and 1-yr follow-up pharmaco-
logical treatment is given in Table 2b.
Patient 1 Patient 2 Patient 3 Patient 4
Patient 5 Patient 6 Patient 7 Patient 8
A=4.5 V
F=135 Hz
D=210 µs
A=4.5 V
F=135 Hz
D=210 µs
A=5 V
F=135 Hz
D=180 µs
A=4 V
F=135 Hz
D=180 µs
A=4.5 V
F=135 Hz
D=180 µs
A=4 V
F=135 Hz
D=180 µs
A=3.5 V
F=135 Hz
D=120 µs
A=3.5 V
F=135 Hz
D=135 µs
Fig. 1. Electrode contacts and current stimulation parameters in every patient. A, Amplitude in volts ; D, pulsewidth in
microseconds ; F, frequency in Hertz. Red circles represent contact cathode and blue circles, contact anode of electrodes.
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DBS outcomes
Seven (87.5%) out of eight patients reached the
response criterion and four (50%) of eight were in re-
mission (HAMD17 f7) in the ﬁrst week after surgery.
This was followed by a general worsening, with
an overall response rate of 37.5% (3/8 patients) at
1 month. From then onwards, patients showed a
progressive improvement : at 6 months, response and
remission rates were, respectively, 87.5% (7/8) and
37.5% (3/8), whereas the corresponding ﬁgures at 1 yr
were 62.5% (5/8) and 50% (4/8). Notably, 3/4
patients, who fulﬁlled remission criteria at the end
of the 1-yr follow-up, had already remitted after
3 months of DBS.
HAMD17 scores were signiﬁcantly improved by
DBS (F=42.3, d.f.=1, 6, p<0.001). Figure 2 displays
the mean and individual changes of HAMD scores
over time. Mood, anxiety, somatic, and sleep subscales
of the HAMD17 were also analysed after 1, 2, 4, 6, 9 and
12 months post-surgery. DBS was eﬀective in all sub-
scales as well as in the global depressive symptoms
(F=1.94, d.f.=24,168, p=0.008, see Table 3).
Further, patients were classiﬁed as responders and
non-responders after 1 yr DBS. There were no diﬀer-
ences between responders and non-responders in
age (47.2 vs. 47.3 yr, respectively), onset of illness (23.6
vs. 27 yr), duration of illness (5.8 vs. 5 yr) or length
of the current depressive episode (6.4 vs. 6.3 yr).
Interestingly, four out of the ﬁve patients who re-
sponded to DBS had partially responded to mainten-
ance ECT before surgery (x2=4.8, p=0.03). As
expected, responders showed a more marked re-
duction of mood and anxiety clusters scores at follow-
up (repeated-measures ANOVA), group eﬀect (mood:
F=9.72, d.f.=1, 6, p=0.02) ; timergroup interaction
(mood: F=2.71, d.f.=6, 36 ; p=0.03 ; anxiety : F=2.67,
d.f.=6, 36, p=0.03, see Table 3).
CGI and MADRS scores were also signiﬁcantly
improved by DBS (t=x5.8, d.f.=7, p=0.001; t=5.5,
d.f.=7, p=0.001, respectively ; Table 3). Neuro-
psychological performance at the time of clinical sta-
bilization (5.8 months on average) was unaﬀected
by DBS. However, all patients reported a better im-
pression about their performance than before DBS
when asked. At the time of writing, the majority of
patients have recovered, or even started leisure ac-
tivities and social relationships, after having been in-
active due to their depressive illness for several years
prior to intervention. Additionally, two patients no
longer require daily support. These are indicators that
DBS would also enhance the psychosocial functioning.
Intra-operative ﬁndings and electrode localization
None of the patients reported acute behavioural or
cognitive eﬀects spontaneously, or after answering
intra-operative stimulation test items. Similarly, no
adverse eﬀect was reported by any patient at a stimu-
lation intensity of 9.0 V in any electrode contact.
Magnetic resonance 1.5 T images were co-registered
on the 3 T images (obtained just before surgery) to
determine localization on the highest quality images.
DBS electrodes were visualized in coronal, axial and
sagittal planes. The tip to be targeted was the single
electrode (16.6 mm long) which included the two ac-
tive contacts (cathode and anode) since all patients
were already receiving bipolar stimulation. Thereafter,
all images where normalized to MNI (Montreal
Neurological Institute) space and coordinates were
deﬁned. The location of the electrodes was set by
using the labels of the nearest grey matter delivered by
the Talairach atlas. Figure 3 shows the approximate
location of electrodes in each patient, obtained after
normalization to a single MNI space. Table 4 shows
the exact location of electrodes according to MNI and
Table 1. Clinical and demographic characteristics of
the sample
Mean (S.D.)
Gender (female/male) 6/2
Marital status
Single (n) 4
Married (n) 4
Years of education 12.5 (3.9)
Age at surgery 47.4 (11.3)
Age at MDD onset 24.9 (5.3)
Length of current episode (yr) 6.3 (1.8)
Previous suicidal attempts (n) 8
Family history of aﬀective disorders (n) 7
Number of previous episodes 5.5 (3.7)
Number of previous hospitalizations 7.5 (5.5)
Patients with melancholic characteristics (n) 6
MADRS
Pre-DBS 28.5 (6.3)
GCI
Pre-DBS 5.1 (0.8)
HAMD17
Pre-DBS 21.3 (2.4)
DBS, Deep brain stimulation; MDD, major depressive
disorder ; MADRS, Montgomery–A˚sberg Depression Rating
Scale ; GCI, Clinical Global Impression scale ; HAMD17,
Hamilton 17-item Depression Rating Scale.
Values represent mean and standard deviation (S.D.) unless
speciﬁed otherwise.
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Talairach stereotaxic coordinates. Spearman’s corre-
lation showed a signiﬁcant relationship between elec-
trode localization (nearest grey matter label in Table 4)
and responders/non-responders at 12 months (r=0.8,
p=0.017). Responders appeared to have electrodes
placed mostly in BA 24, corpus callosum and head of
caudate, whereas non-responders had a predominant
location near BA 25.
Incidents and adverse events
Surgical procedure and post-operative period was
well-tolerated for all patients. Few adverse events
were observed: two patients reported cephalalgia, and
three reported pain in the neck at the site of the sub-
dermal cable. In all eight patients there were no other
adverse events reported by previous studies, such as
wound infection, scalp cellulitis or seizures. One ex-
planation for the lack of infections, already suggested
by Mayberg et al. (2005), relies on the fact that all
patients had the electrodes and the pulse generator
inserted in a single surgical intervention.
One patient, after having displayed an initial
clinical improvement, attempted suicide 4 months
after starting DBS, which required hospitalization.
This patient did not fulﬁl response criteria at 6 and
12 months’ post-surgery, although she still achieved a
certain improvement in her psychosocial functioning.
On the other hand, two of the ﬁve ﬁnal responders
displayed a severe depressive recurrence during the
ﬁrst 3–4 months after starting DBS. One of them, who
was on maintenance ECT before DBS, was treated
again with nine sessions of ECT, achieving and main-
taining remission criteria since then (see Puigdemont
et al. 2009 for more details).
Discussion
The present study conﬁrms and extends previous ob-
servations on the usefulness of DBS to treat depressive
symptoms in patients suﬀering from severe TRD.
These ﬁndings represent the second independent ser-
ies of DBS of the subgenual cingulate gyrus (SCG) and
conﬁrm that SCG-DBS produces robust improvements
in TRD. Indeed, seven (87%) patients responded sig-
niﬁcantly after 6 months of chronic stimulation and
50% remitted after 1 yr of DBS. Response rates in our
study are similar or greater than those reported in
previous studies (Bewernick et al. 2010; Kennedy et al.
2011; Lozano et al. 2008; Malone et al. 2009; Mayberg
et al. 2005; Schlaepfer et al. 2008). In this regard, a re-
cent longitudinal study by Kennedy et al. (2011) has
reported a response rate of 60% after 1 yr of stimu-
lation, which is reasonably maintained after 3 yr of
DBS. As reported by Lozano et al. (2008) the maximal
clinical improvement was observed after several
months of chronic stimulation reaching a plateau after
6 months. Interestingly, clinical evolution during the
ﬁrst 3 months did not predict ﬁnal outcomes : early
worsening and recurrences were observed even in
Table 2a. Summary of previous treatments to which patients developed resistance
Patient 1
(female)
Patient 2
(female)
Patient 3
(female)
Patient 4
(female)
Patient 5
(female)
Patient 6
(female)
Patient 7
(female)
Patient 8
(female)
Pharmacological treatments
TCAs 2 3 3 2 2 1 3 2
MAOIs 2 2 2 2 1 1 1 0
SSRIs 2 1 1 3 5 1 2 2
SNRIs 2 2 2 2 2 2 2 1
Others 4 4 3 2 2 2 No No
Potentiation 5 2 4 5 3 2 1 2
Mood stabilizers 3 4 5 2 1 2 2 3
Drug combinations Yes Yes Yes Yes Yes Yes Yes Yes
ECT Yes Yes Yes Yes Yes Yes Yes Yes
Psychotherapy No Yes Yes Yes Yes Yes No Yes
TCAs, Tricyclic antidepressants (imipramine, clomipramine, amitriptyline, nortriptyline) ; MAOIs, monoamine oxidase
inhibitors (phenelzine, tranylcypromine, moclobemide) ; SSRIs, selective serotonin reuptake inhibitors (ﬂuoxetine, ﬂuvoxamine,
paroxetine, citalopram, sertraline) ; SNRIs, venlafaxine, duloxetine ; Others, mianserine, mirtazapine, reboxetine, trazodone ;
Potentiation : with lithium, methylphenidate, triiodothyronine, pindolol, tryptophan, atypical antipsychotics ; Mood stabilizers :
lithium, valproate, lamotrigine, carbamazepine ; ECT, electroconvulsive therapy.
Values are the number of drugs of each class attempted at adequate dosages and periods.
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patients who ﬁnally responded. However, patients
remitted at 3 months maintained remission criteria
until the end of the 1 yr follow-up.
Regarding intra-operative eﬀects, none of our
patients noticed the initiation of electrode stimulation.
Mayberg et al. (2005) reported subjective experiences,
Table 2b. Detailed description of pre-DBS and 1-yr follow-up pharmacological
treatment per each patient
Pharmacological treatment
pre-DBS
Pharmacological treatment
1-yr follow-up
Patient 1 Duloxetine (300 mg/d) Duloxetine (300 mg/d)
Mianserine (60 mg/d) Mianserine (60 mg/d)
Pregabaline (900 mg/d) Pregabaline (600 mg/d)
Lithium (600 mg/d) Lithium (400 mg/d)
Quetiapine (400 mg/d) Quetiapine (400 mg/d)
Clonazepam (2 mg/d) Clonazepam (1.5 mg/d)
Patient 2 Duloxetine (120 mg/d) Duloxetine (120 mg/d)
Olanzapine (20 mg/d) Quetiapine (1000 mg/d)
Lorazepam (2 mg/d)
Patient 3 Venlafaxine (300 mg/d) Venlafaxine (300 mg/d)
Mirtazapine (60 mg/d) Mirtazapine (60 mg/d)
Lithium 400 mg/d Lithium (400 mg/d)
Diazepam (30 mg/d) Diazepam (30 mg/d)
Quetiapine (150 mg/d) Quetiapine (150 mg/d)
Ziprasidone 80 mg/d
Patient 4 Fluvoxamine (200 mg/d) Escitalopram (40 mg/d)
Clomipramine (100 mg/d) Mianserine (60 mg/d)
Pregabaline (150 mg/d) Pregabaline (150 mg/d)
Flunitrazepam (1 mg/d) Diazepam (25 mg/d)
Quetiapine (50 mg/d)
Patient 5 Duloxetine (90 mg/d) Duloxetine (90 mg/d)
Mirtazapine (30 g/d) Mirtazapine (30 mg/d)
Olanzapine (15 mg/d) Olanzapine (5 mg/d)
Diazepam (62.5 mg/d) Diazepam (50 mg/d)
Alprazolam (6 mg/d) Alprazolam (6 mg/d)
Zolpidem (10 mg/d) Zolpidem (10 mg/d)
Levomepromazine (50 mg/d) Levomepromazine (50 mg/d)
Pregabaline (300 mg/d)
Patient 6 Duloxetine (120 mg/d) Duloxetine (120 mg/d)
Mirtazapine (60 mg/d) Mirtazapine (60 mg/d)
Valproate (1500 mg/d) Valproate (1500 mg/d)
Levomepromazine (100 mg/d) Trazodone (200 mg/d)
Trazodone (200 mg/d) Lorazepam (5 mg/d)
Lorazepam (5 mg/d) Midazolam (7.5 mg/d)
Midazolam (7.5 mg/d)
Alprazolam (1.5 mg/d)
Patient 7 Imipramine (150 mg/d) Imipramine (150 mg/d)
Zolpidem (10 mg/d) Medazepam (10 mg/d)
Medazepam (10 mg/d)
Patient 8 Clomipramine (250 mg/d) Clomipramine (250 mg/d)
Lamotrigine (400 mg/d) Lamotrigine (400 mg/d)
Quetiapine (50 mg/d) Quetiapine (50 mg/d)
Clorazepate (30 mg/d) Clorazepate (10 mg/d)
Lormetazepam (1 mg/d)
Drugs that were ruled out or diminished after 1 yr are underlined. Drugs that have
been changed or introduced after 1 yr are in bold.
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but this has not been further reported. However, our
patients did show a post-surgery improvement within
the ﬁrst 2 wk, with a subsequent transient worsening.
This phenomenon could be explained a priori by a
placebo eﬀect although it has been partly related to a
micro lesion in the treatment of Parkinson’s disease
and essential tremor, where transient clinical im-
provements can be evoked solely by the introduction
of electrodes (Malteˆte et al. 2009; Morishita et al. 2010).
A similar eﬀect could also occur in the treatment of
chronic major depression (Lozano et al. 2008). In our
case, this initial beneﬁt did not predict the subsequent
evolution of patients.
Indeed, one of the most intriguing questions in
DBS is why some TRD patients do respond to DBS
while others do not. Our results demonstrated a re-
lationship between previous partial responses to ECT
and response to DBS. This observation suggests that
previous response to ECT is a predictor of DBS out-
comes, although – due to the small sample size – this
cannot be fully clariﬁed. Taking into account the
limitations and side-eﬀects of ECT in prolonged
maintenance regimens, DBS may be an excellent
therapeutic alternative for treating TRD without en-
tailing memory loss or cognitive dysfunction. More-
over, DBS has proven to be well-tolerated and
compatible with ECT (see Puigdemont et al. 2009 for a
case report).
Furthermore, SCG-DBS might enhance ECT eﬃcacy
in patients with previous partial response to the latter
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Fig. 2. Eﬀect of deep brain stimulation (DBS) of the subcallosal gyrus (SCG) on the 17-item Hamilton Depression Rating Scale
(HAMD17). Upper panel : Mean¡S.D. change of HAMD17 for all patients in the study. Lower panels : Individual changes of
HAMD17 (w, week ; m, month). * p<0.01, ** p<0.001 vs. inclusion.
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treatment, given that, when a relapse occurs after the
implantation of the neurostimulator, ECT yielded a
better sustained response. A common mechanism of
action in terms of the electrophysiological eﬀects
could be claimed for both DBS and ECT, although
more research is required. In any case, the above
data indicate that DBS is not an endpoint for the
treatment of implanted patients, but a strategy that
can allow new intentions of previously ineﬀective
antidepressant treatments if these patients suﬀer a
relapse.
Interestingly, changes in clinical symptoms, as
measured with the HAMD subscales, were diﬀerent in
responders and non-responders, where those patients
who responded displayed a greater improvement in
mood and anxiety. Previous studies have also re-
ported the decrease in anxiety (Bewernick et al. 2010)
and core depressive symptoms (Lozano et al. 2008) as
being responsible of the general improvement of im-
planted patients. The present results show that DBS of
SCG evokes an overall eﬀect on all HAMD subscales,
including anxiety symptoms.
The neurobiological basis of the antidepressant
eﬀects of SCG-DBS is presently unknown, due to
the poor knowledge of brain circuits involved in the
pathophysiology and treatment of major depression.
Based on alterations of brain energy metabolism in
depressed patients, a model involving cortical, limbic
and thalamic areas has been put forward (Seminowicz
et al. 2004) in which SCG areas play key roles. The
enhanced activity of some of these areas (including
Cg25) seen in untreated depressed patients decreases
after psychological (cognitive behavioural therapy)
and antidepressant drug treatments (Seminowicz
et al. 2004). Thus, DBS may normalize an altered
function of cortico-limbic and cortico-thalamic net-
works by removing an altered input from SCG
onto other frontal areas. Further, given the strong re-
ciprocal connectivity between the prefrontal cortex
and the brainstem monoaminergic nuclei, where the
cell bodies of ascending serotonergic, noradrenergic
and dopaminergic neurons are located (see for
review Groenewegen & Uylings, 2000), SCG-DBS
may normalize a putative monoaminergic hypofunc-
tion secondary to abnormal inputs from prefrontal
cortex.
Previous studies failed to ﬁnd a relationship be-
tween the location of active electrode contacts and
treatment outcome (Hamani et al. 2009). However, our
results show a relationship between long-term re-
sponse (1 yr) and electrode location, indicating the
requirement of SCG stimulation, but not necessarily of
Cg25. Unlike in Mayberg’s studies, stimulating Cg25
(Hamani et al. 2009; Lozano et al. 2008; Mayberg et al.
2005), most responder patients in the present study
had their electrodes in Cg24 (some also in corpus
callosum and head of caudate). This diﬀerence may
be due to several factors. On the one hand, we used
bipolar stimulation in our patients whereas previous
studies in the SCG by Mayberg’s group have used
monopolar stimulation. Indeed, both procedures
result in diﬀerent excitation of nerve ﬁbres (Yokoyama
et al. 2001) probably aﬀecting diﬀerent aﬀerent and
eﬀerent areas to the stimulation site. On the other
hand, DBS drives focal activity at the immediate tar-
get, which, in turn, leads to inhibition or excitation in
adjacent and remote areas to which it is connected. As
hypothesized by Hamani et al. (2009), stimulation
Table 3. Eﬀects of DBS on HAMD17 subscales, MADRS and CGI scores
Pre-DBS 1 wk after 2 wk after
1 month
after
2 months
after
4 months
after
6 months
after
9 months
after
12 months
after
HAMD17
Mood 9.5 (2.3) 4.7 (2.8)* 6.3 (2.4)* 6 (3.7)+ 4.6 (3.7)* 4.8 (2.9)* 3.5 (2.6)** 2.4 (2.4)** 3.9 (4.6)*
Anxiety 5.8 (1.5) 2.3 (1.7)** 3.9 (2.6) 4.8 (3.1) 3.6 (2.6)+ 3.3 (2.1)* 1.9 (1.7)** 2.1 (1.6)** 2.8 (1.9)*
Insomnia 2.3 (1.4) 1 (0.9)* 1.1 (1.5) 1.4 (1.8) 0.9 (1.1)* 0.6 (0.9)** 0.1 (0.4)** 0.4 (1.1)** 0.6 (1.2)*
Somatization 3.5 (1.2) 2.4 (1.2)+ 2.8 (1) 2.9 (1.4) 3 (1.4) 2.6 (0.7)+ 2.4 (1.1)+ 1.8 (0.9)** 1.6 (0.9)**
MADRS 28.5 (6.3) 10.8 (11.3)
CGI 5.1 (0.8) 2.1 (1.4)
HAMD17, Hamilton 17-item Depression Rating Scale ; MADRS, Montgomery–A˚sberg Depression Rating Scale ; GCI, Clinical
Global Impression scale.
Values represent mean (S.D.).
**p=0.001,* p=0.01,+ p=0.05 for diﬀerences from pre-DBS scores.
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within distinctive regions along the SCG should lead
to varied outcomes due to the recruitment of diﬀerent
ﬁbre systems, i.e. more anterior contact location would
probably aﬀect the cingulate bundle, whereas more
posterior active contacts would aﬀect a more complete
set of projections to and from SCG. Intriguingly, un-
like in Hamani et al. (2009), our results appear to con-
ﬁrm this view. This diﬀerence may be explained by
the putative involvement of the areas in which our
patients had the electrodes implanted (e.g. corpus
callosum stimulation will evoke an immediate depo-
larization blockade of stimulated axons, as if DBS were
applied in the cortical area containing the cell bodies).
Limitations
Despite the novelty of the present ﬁndings (second
independent study of SCG-DBS), the study has some
limitations. First is the limited sample size, which
prevented us establishing predictors of response to
DBS. However, reporting the present results can help
to establish DBS as a therapeutic tool in the treatment
of resistant depression. A second limitation, in com-
mon with previous DBS studies in depression, is the
lack of a control group, due to ethical reasons (e.g.
dummy DBS in chronic TRD patients). This limitation
will be partly solved in the current cross-over phase
of the present trial. Last, a weakness of our study is
the lack of functional neuroimaging data in order
to understand brain metabolic changes induced
by DBS.
Conclusions
These ﬁndings report the second independent
study on the use of DBS of the SCG to treat de-
pression resistant to current therapeutic strategies.
DBS of the SCG was able to induce a full remission
in four out of the eight patients included after 1 yr
(sagittal XMNI=–9) (sagittal XMNI=–6) (sagittal XMNI=–3)
(sagittal XMNI=0) (sagittal XMNI=3)
(sagittal XMNI=9) (sagittal XMNI=12)
(sagittal XMNI=6)
Fig. 3. Location of the electrode contacts on a sagittal view of the cingulate gyrus. Circles are schematic representations of the
electrode contacts in patients responding (green circles) and not responding (red circles) to DBS of the SCG. Numbers
correspond to every patient. More detailed information is given in Table 4.
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of stimulation. Clinical eﬀects were seen in all
HAMD17 subscales without a signiﬁcant incidence of
side-eﬀects. On the other hand, responses appear to
depend on electrode localization, with most responder
patients having electrodes localized in BA 24,
corpus callosum and head of caudate. Similarly,
early responses did not predict the ﬁnal outcome at
1 yr. Finally, all patients with previous partial re-
sponses to maintenance ECT showed good responses
to DBS.
Table 4. Bilateral single point localization of electrodes in each patient in both MNI and Talairach coordinates
MNI Talairach Single point Nearest grey matter
Patient 1
Left negative x2, 20,x18 x3, 18,x10 Left anterior cingulate Left anterior cingulate BA 25
Left positive x2, 20,x15 x3, 18,x8 Left anterior cingulate Left anterior cingulate BA 25
Right negative 5, 19,x16 4, 17,x8 Right anterior cingulate Right anterior cingulate BA 25
Right positive 5, 19,x13 4, 17,x6 Right anterior cingulate BA 25 Right anterior cingulate BA 25
Patient 2
Left negative x3, 17,x14 x4, 15,x7 Left anterior cingulate BA 25 Left anterior cingulate BA 25
Left positive x4, 19,x9 x5, 17,x2 Left extra-nuclear WM Left caudate head
Right negative 9, 16,x15 8, 14,x8 Right anterior cingulate WM Right caudate head
Right positive 8, 18,x10 7, 16,x3 Right extra-nuclear WM Right caudate head
Patient 3
Left negative x0, 13,x17 x1, 12,x10 Left anterior cingulate Left anterior cingulate BA 25
Left positive x0, 14,x14 x1, 13,x7 Left anterior cingulate Left anterior cingulate BA 25
Right negative 9, 14,x14 8, 12,x7 Right anterior cingulate WM Right caudate head
Right positive 10, 15,x12 8, 13,x5 Right caudate head Right caudate head
Patient 4
Left negative x2, 10,x7 x3, 8,x1 Left extra-nuclear WM Left caudate head
Left positive x2, 11,x5 x3, 9, 1 Left lateral ventricle Left caudate head
Right negative 8, 12,x9 7, 10,x3 Right caudate head Right caudate head
Right positive 8, 13,x7 7, 11,x1 Right caudate head Right caudate head
Patient 5
Left negative x3, 26,x13 x4, 24,x5 Left anterior cingulate BA 24 Left anterior cingulate BA 24
Left positive x3, 26,x11 x4, 23,x3 Left anterior cingulate BA 24 Left anterior cingulate BA 24
Right negative 4, 27,x9 3, 24,x1 Right corpus callosum Right anterior cingulate BA 24
Right positive 4, 28,x6 3, 25, 1 Right corpus callosum Right anterior cingulate BA 24
Patient 6
Left negative x0, 24,x8 x1, 21,x1 Inter-hemispheric Left anterior cingulate BA 24
Left positive x0, 24,x5 x1, 21, 2 Inter-hemispheric Left anterior cingulate BA 24
Right negative 13, 22,x9 11, 19,x2 Right caudate head Right caudate head
Right positive 13, 22,x6 11, 19, 1 Right caudate head Right caudate head
Patient 7
Left negative x9, 27,x20 x9, 25,x12 Left medial frontal gyrus WM Left medial frontal gyrus BA 11
Left positive x9, 29,x15 x9, 27,x7 Left anterior cingulate WM Left anterior cingulate BA 24
Right negative 5, 26,x14 4, 24,x6 Right anterior cingulate BA 24 Right anterior cingulate BA 24
Right positive 5, 26,x9 4, 23,x2 Right corpus callosum Right anterior cingulate BA 24
Patient 8
Left negative x6, 29,x3 x6, 26, 4 Left corpus callosum Left caudate head
Left positive x6, 29,x5 x6, 26, 2 Left corpus callosum Left anterior cingulate BA 24
Right negative 3, 28,x4 2, 25, 3 Right corpus callosum Right anterior cingulate BA 24
Right positive 4, 28,x6 3, 25, 1 Right corpus callosum Right anterior cingulate BA 24
MNI, Montreal Neurological Institute space ; WM, white matter ; BA, Brodmann area.
Last column corresponds to nearest grey matter, when the electrode was placed elsewhere.
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